Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook

The key factor in the current scenario for next-generation omics-based diagnostic technologies is the level of accuracy in the results, followed by the capacity to detect early, and cost. Cost currently remains a major constraint, as people and healthcare institutes are skeptical of investing in technologies that have not provided very wide and acceptable results. The impact of cost constraints will diminish as the cost/value benefit is established. The future market will demand reliability, which means reproducible results on standard equipment, and techniques with less deviation across laboratories and methodologies. The importance of accuracy remains constant. Industry participants will continue to position their diagnostic products based on accuracy levels. Emphasis will also remain on its capacity to test the probability of disease as early as possible through a non-invasive method of diagnosis.
The report discusses drivers, restraints, challenges and opportunities and market estimates of the global diagnostics market in genomics, proteomics and metabolomics on the basis of:
• Technologies
• Applications
• Strategic issues and innovations


Key features of this report


• Measures the global diagnostics market with respect to technologies and applications
• Analyzes the market with respect to drivers, restraints, challenges, opportunities and market estimates
• Identifies trends and innovations in the markets analyzed
• Analyzes and forecasts the revenues of regional market segments
• In-depth analysis of competitive landscape, top-selling products and services


Scope of this report


• Understanding the existing and emerging applications of diagnostic in the three omics technologies of proteomics, genomics and metabolomics.
• Analyses of the products and technological developments in the market.
• Understanding of the various applications and their importance in the development of new diagnostics products
• Many novel tests such as mass spectrometry and microarrays are expected to make a significant difference in the prognosis, monitoring and diagnosis of cancer patients..


Key Market Issues


• Past and current trends are still dominated by symptom based diagnosis.
• However, current healthcare objectives focus on early detection.
• The future is about genetic study and disease pre-disposition, which will test the probability of acquiring a disease or a disorder, enabling precautionary steps.
• Evolving technology development based on omics technologies are making diagnostic tests less expensive.
• Accuracy remains the key demand for next generation omics based diagnostics.

Key findings from this report


• Mass spectrometry is used to identify potential circulating protein biomarkers for non-small cell lung cancer.
• Omics and diagnostics have been helpful in the diagnosis of H1N1, but genome-based techniques have proved vital in identifying the strain of the virus.
• Genome sequencing remains the most challenging task, as it requires a great deal of time and investment.
• Biomarkers in omics have contributed greatly to the early diagnosis of cancer.

Key questions answered


• What are the existing and pipeline technologies and products in the diagnostics market?
• What are the major application areas of diagnostics?
• What are the key market developments of the top companies profiled in this report?
• What are the trends and innovations in the global diagnostics market?



Report Highlights
Companies mentioned in the report: AFFYMETRIX , AGILENT TECHNOLOGIES , AMGEN , BG MEDICINE , BIOPHYSICAL CORP , GENEDATA , CALIBRANT , CAPRION PROTEOMICS , GE HEALTHCARE
[Studien Infos ausblenden]

Table of Contents
Genomics, proteomics and metabolomics in diagnostics
Executive summary 14
Market overview 14
Biomarkers 14
Microarrays and microfluidics 16
Lab-on-a-chip proteomics 16
Bioinformatics 17
Emerging applications 18
Applications market 18
Competitive landscape 19
Patent analysis 20
Geographic analysis 20
Company profiles 21
Chapter 1 Market overview 24
Summary 24
Emerging trends focus on survival rates and non-invasive methods 25
Accuracy remains the key for next generation omics-based diagnostics 26
Biomarkers setting standards for ideal diagnostic methodology 27
Key market drivers & resistors 29
Chapter 2 Biomarkers 32
Summary 32
Defining biomarkers 33
The biomarker market 33
Market drivers 33
Restraints 35
Emerging applications of biomarkers 37
Omics technologies 37
Disease predisposition 38
Pre-natal testing 38
Biomarkers and translational medicine 38
Proteomics and biomarker applications 39
Post-genomic biomarker technologies 39
Innovative technologies provide patient centric data 39
Genomic technologies play a significant role in nutritional research 40
Molecular diagnostics 40
Mass spectrometry (MS) 40
Gel electrophoresis 41
Metabolomics 42
Imaging biomarkers 42
Confluence of diagnostics and pharmaceutical companies 43
Challenges 43
High investment hampers advance biomarker research 43
Validation challenge 44
Lack of IT solutions 44
Chapter 3 Microarrays and microfluidics 46
Summary 46
Microarrays and microfluidics 47
Market drivers 47
Market restraints 49
DNA microarrays 51
Fabrication technologies 51
Printing with fine-pointed pins onto glass slides 51
Photolithography using pre-made masks 52
Ink-jet printing 52
Analytical methods 52
mRNA profiling 53
Genetic imbalance detection 53
Gene expression profiling 53
SNP detection 54
DNA microarrays in in vitro diagnostics (IVD) 54
Protein microarrays 55
Protein immobilization strategies 56
Surface chemistries 56
Format of protein chips 56
Complete protein profiling utility 57
Tissue and cell microarrays 58
Chapter 4 Lab-on-a-chip proteomics 60
Summary 60
Introduction 61
Classification of LOCs 61
Market drivers for LOC 62
Drawbacks 64
Chapter 5 Bioinformatics 66
Summary 66
Introduction 67
Market drivers 67
Market restraints 68
Applications in diagnostics 70
Strategic recommendations 72
Advancements in molecular diagnostics and bioinformatics 73
Chapter 6 Emerging applications 76
Summary 76
Quantitative real-time polymerase chain reaction (qPCR) 77
DNA biosensors 78
Flow cytometry 78
DNA methylation 79
Nanotechnology 80
Other novel diagnostic applications 81
DNA testing technologies 81
Mass spectrometry and proteomics 81
H1N1 82
Metabolomics and related diagnosis 82
MicroRNA 83
Use of protein microarrays for early detection of disease 83
Next-generation sequencing technologies and IT technologies 84
Biomarkers 85
Chapter 7 Applications market 88
Summary 88
Application by utility 89
Sequence analysis 90
Structure analysis 91
Function analysis 91
Application by disease 91
Cancer 92
Infectious disease 92
HIV 93
Autoimmune diseases 93
Neurological disorders 93
Cardiovascular and metabolic disease 94
Chapter 8 Competitive landscape 96
Summary 96
Agreements and collaborations 97
New product/service launches 102
Mergers and acquisitions 103
Chapter 9 Patent analysis 106
Summary 106
Introduction 107
Patents by technology 108
Patents by geography 110
Patents by assignee 112
Chapter 10 Geographic analysis 116
Summary 116
Global diagnostics market 117
North America 117
Europe 119
Asia 120
Rest of the World (ROW) 121
Chapter 11 Company profiles 124
Summary 124
Affymetrix 125
Company overview 125
Products and services 125
Strategy and developments 126
Agilent Technologies 126
Company overview 126
Products and services 126
Strategy and developments 127
Amgen 127
Company overview 127
Products and services 128
Strategy and developments 128
Beckman Coulter 128
Company overview 129
Products and services 129
Strategy and developments 129
Bio-Rad Laboratories 129
Company overview 130
Product and services 130
Strategy and developments 130
BG Medicine 130
Company overview 130
Products and services 131
Strategy and developments 131
Biophysical Corp 132
Company overview 132
Products and services 132
Strategy and developments 132
BioSystems International (BSI) 133
Company overview 133
Products and services 133
Strategy and developments 134
Calibrant 134
Company overview 134
Products and services 135
Strategy and development 135
Caprion Proteomics 135
Company overview 135
Products and services 136
Strategy and developments 136
deCODE Genetics 136
Company overview 137
Products and services 137
Strategy and developments 137
Exagen Diagnostics 137
Company overview 138
Products and services 138
Strategy and developments 138
GE Healthcare 138
Company overview 139
Strategy and developments 139
Genedata 140
Company overview 140
Products and services 140
Strategy and developments 140
GeneNews 141
Company overview 141
Products and services 141
Strategy and developments 142
Human Metabolome Technologies (HMT) 142
Company overview 142
Products and services 143
Strategy and developments 143
Illumina, Inc. 143
Company overview 143
Products and services 144
Strategy and development 144
Imgenex 144
Company overview 145
Products and services 145
Strategy and developments 145
InforSense 145
Company overview 146
Products and services 146
Strategy and developments 146
Integromics 146
Company overview 147
Products and services 147
Strategy and developments 147
MDS, Inc. 147
Company overview 148
Products and services 148
Strategy and developments 148
Metabolon, Inc. 148
Company overview 149
Products and services 149
Strategy and developments 149
Metanomics Health GmbH 149
Company overview 150
Products and services 150
Strategy and developments 150
Microchip Biotechnologies 150
Company overview 151
Products and services 151
Strategy and developments 151
MicroDiscovery 151
Company overview 151
Products and services 152
Strategy and developments 152
Molecular Connections 152
Company overview 152
Products and services 153
Strategy and developments 153
NextGen Group PLC 153
Company overview 153
Products and services 153
Strategy and developments 154
Nonlinear USA, Inc. 154
Company overview 154
Products and services 155
Strategy and developments 155
Nuvera Biosciences 155
Company overview 155
Products and services 156
Strategy and developments 156
Ocimum Biosolutions 156
Company overview 156
Products and services 157
Strategy and developments 157
Pam Gene BV 157
Company overview 157
Products and services 157
Strategy and developments 158
Siemens Healthcare 158
Company overview 158
Products and services 158
Strategy and developments 158
Chapter 12 Appendix 160
Patents 160
Methodology 185

[Inhaltsverzeichnis ausblenden]

List of Figures
Figure 1.1: Evolving trends in diagnostics 25
Figure 1.2: Key features of next generation omics-based diagnostic technologies 27
Figure 2.3: Key market drivers for biomarkers 34
Figure 2.4: Key market restraints for biomarkers 36
Figure 3.5: Key market drivers for microarrays & microfluidics 48
Figure 3.6: Key market restraints for microarrays & microfluidics 50
Figure 5.7: Key market drivers for bioinformatics 68
Figure 5.8: Key market restraints for bioinformatics 69
Figure 5.9: Evolution of bioinformatics 71
Figure 8.10: Diagnostic companies strategies 97
Figure 8.11: Recent developments: agreements & collaborations, 2008 - Jan 10 98
Figure 8.12: Mergers and acquisitions, 2008 - 09 103
Figure 9.13: Total number of patents registered, 2006–09 107
Figure 9.14: Patents by technology, 2006-09 109
Figure 9.15: Patents by geography, 2006-09 110
Figure 9.16: Patents by geography and technology, 2006–09 111
Figure 9.17: Patents by assignee, 2008 113
Figure 10.18: North American diagnostics market ($m), 2007–14 118
Figure 10.19: European diagnostics market($m), 2007–14 119
Figure 10.20: Asian diagnostics market($m), 2007–14 121
Figure 10.21: RoW diagnostics market ($m), 2007–14 122
List of Tables
Table 1.1: Global omics-based diagnostic technology market ($m), 2007-14 28
Table 2.2: Global biomarker market, by geography, ($m) 2007–14 37
Table 3.3: Global microarray market, by products, ($m) 2007–14 50
Table 3.4: Global microarray market, by geography, ($m) 2007–14 51
Table 3.5: Global DNA microarray market, by geography, ($m) 2007–14 55
Table 3.6: Global protein microarray market, by geography, ($m) 2007–14 57
Table 3.7: Global tissue/cell microarray market, by geography, ($m) 2007–14 58
Table 4.8: Global LOC market, by geography, ($m) 2007–14 64
Table 5.9: Global bioinformatics market, by geography, ($m) 2007–14 69
Table 6.10: Global qPCR market, by geography, ($m) 2007–14 77
Table 6.11: Global DNA biosensors market, by geography, ($m) 2007–14 78
Table 6.12: Global flow cytometry market, by geography, ($m) 2007–14 79
Table 6.13: Global DNA methylation market, by geography, ($m) 2007–14 80
Table 6.14: Global nanotechnology market, by geography, ($m) 2007–14 81
Table 7.15: Global diagnostics market, by utility, 2007–14 ($m) 90
Table 7.16: Global diagnostics market, by diseases, 2007–14 ($m) 92
Table 8.17: Details of recent agreements & collaborations 99
Table 8.18: Details of recent agreements & collaborations (ctd1) 100
Table 8.19: Details of recent agreements & collaborations (ctd2) 101
Table 8.20: Details of recent new product/service/technology launches 102
Table 8.21: Details of recent M&A activity 104
Table 10.22: Omics-based diagnostics market, by geography, ($m) 2007-14 117
Table 12.23: Japanese patents 160
Table 12.24: Japanese patents (ctd1) 161
Table 12.25: Japanese patents (ctd2) 162
Table 12.26: Japanese patents (ctd3) 163
Table 12.27: Japanese patents (ctd4) 164
Table 12.28: US patents 165
Table 12.29: US patents (ctd1) 166
Table 12.30: US patents (ctd2) 167
Table 12.31: US patents (ctd3) 168
Table 12.32: US patents (ctd4) 169
Table 12.33: US patents (ctd5) 170
Table 12.34: US patents (ctd6) 171
Table 12.35: US patents (ctd7) 172
Table 12.36: US patents (ctd8) 173
Table 12.37: US patents (ctd9) 174
Table 12.38: US patents (ctd10) 175
Table 12.39: US patents (ctd11) 176
Table 12.40: European patents 177
Table 12.41: European patents (ctd1) 178
Table 12.42: European patents (ctd2) 179
Table 12.43: European patents (ctd3) 180
Table 12.44: European patents (ctd4) 181
Table 12.45: European patents (ctd5) 182
Table 12.46: European patents (ctd6) 183
Table 12.47: European patents (ctd7) 184
Table 12.48: European patents (ctd8) 185

n/a
[Tabellenverzeichnis ausblenden]